{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:49Z","timestamp":1791828589672,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40744-021-00360-6","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T07:04:19Z","timestamp":1630047859000},"page":"1603-1616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis"],"prefix":"10.1007","volume":"8","author":[{"given":"Steven L.","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F. L.","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Farah","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Radford-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-3418","authenticated-orcid":false,"given":"Philip C.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"issue":"2","key":"360_CR1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41584-020-00552-4","volume":"17","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, van der Linden S, Khan MA, Taylor WJ. Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nat Rev Rheumatol. 2020;17(2):109\u201318.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"360_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40744-019-0146-6","volume":"6","author":"PC Robinson","year":"2019","unstructured":"Robinson PC, Sengupta R, Siebert S. Non-radiographic axial spondyloarthritis (nr-axSpA): advances in classification, imaging and therapy. Rheumatol Ther. 2019;6(2):165\u201377.","journal-title":"Rheumatol Ther"},{"key":"360_CR3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","volume":"78","author":"S Siebert","year":"2019","unstructured":"Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis. 2019;78:1015\u20138.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"360_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","volume":"16","author":"AR Moschen","year":"2019","unstructured":"Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16(3):185\u201396.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"360_CR5","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1053\/j.gastro.2010.12.002","volume":"140","author":"Z Hovhannisyan","year":"2011","unstructured":"Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology. 2011;140(3):957\u201365.","journal-title":"Gastroenterology"},{"issue":"12","key":"360_CR6","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1097\/MIB.0b013e3182a85709","volume":"19","author":"A Ueno","year":"2013","unstructured":"Ueno A, Jijon H, Chan R, Ford K, Hirota C, Kaplan GG, et al. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013;19(12):2522\u201334.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"360_CR7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2020.06.022","volume":"53","author":"WP Chong","year":"2020","unstructured":"Chong WP, Mattapallil MJ, Raychaudhuri K, Bing SJ, Wu S, Zhong Y, et al. The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24. Immunity. 2020;53(2):384\u201397 (e5).","journal-title":"Immunity"},{"issue":"11","key":"360_CR8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol. 2016;111(11):1599\u2013607.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"360_CR9","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"issue":"1","key":"360_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","volume":"52","author":"S Fujino","year":"2003","unstructured":"Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65\u201370.","journal-title":"Gut"},{"issue":"11\u201312","key":"360_CR11","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","volume":"34","author":"G Cullen","year":"2011","unstructured":"Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11\u201312):1318\u201327.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"360_CR12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","volume":"48","author":"D Fouache","year":"2009","unstructured":"Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford). 2009;48(7):761\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"360_CR13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","volume":"52","author":"R Seror","year":"2013","unstructured":"Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, et al. Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey. Rheumatology (Oxford). 2013;52(5):868\u201374.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"360_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/annrheumdis-2017-212328","volume":"77","author":"R Charlton","year":"2018","unstructured":"Charlton R, Green A, Shaddick G, Snowball J, Nightingale A, Tillett W, et al. Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. Ann Rheum Dis. 2018;77(2):277\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"360_CR15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jaad.2018.06.024","volume":"79","author":"KA Orrell","year":"2018","unstructured":"Orrell KA, Murphrey M, Kelm RC, Lee HH, Pease DR, Laumann AE, et al. Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: postmarketing analysis from the RADAR (\u201cresearch on adverse drug events and reports\u201d) program. J Am Acad Dermatol. 2018;79(4):777\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"360_CR16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"360_CR17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","volume":"71","author":"P Mease","year":"2019","unstructured":"Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arthritis Care Res (Hoboken). 2019;71(3):367\u201378.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"360_CR18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441\u20138 (e2).","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"360_CR19","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","volume":"59","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2020;59(12):3834\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"360_CR20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","volume":"10","author":"A Armstrong","year":"2020","unstructured":"Armstrong A, Paul C, Puig L, Boehncke WH, Freeman M, Torii H, et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol Ther (Heidelb). 2020;10(1):133\u201350.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"360_CR21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233781","volume":"15","author":"J Burisch","year":"2020","unstructured":"Burisch J, Eigner W, Schreiber S, Aletaha D, Weninger W, Trauner M, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PLoS ONE. 2020;15(5): e0233781.","journal-title":"PLoS ONE"},{"issue":"4","key":"360_CR22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","volume":"50","author":"A Yamada","year":"2019","unstructured":"Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019;50(4):373\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"360_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"issue":"8","key":"360_CR24","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","volume":"76","author":"P Carron","year":"2017","unstructured":"Carron P, Varkas G, Cypers H, Van Praet L, Elewaut D, Van den Bosch F, et al. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study. Ann Rheum Dis. 2017;76(8):1389\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"360_CR25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","volume":"27","author":"S Yusuf","year":"1985","unstructured":"Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335\u201371.","journal-title":"Prog Cardiovasc Dis"},{"issue":"14","key":"360_CR26","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/sim.6844","volume":"35","author":"JJ Shuster","year":"2016","unstructured":"Shuster JJ, Walker MA. Low-event-rate meta-analyses of clinical trials: implementing good practices. Stat Med. 2016;35(14):2467\u201378.","journal-title":"Stat Med"},{"issue":"1","key":"360_CR27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jrsm.1039","volume":"3","author":"JJ Shuster","year":"2012","unstructured":"Shuster JJ, Guo JD, Skyler JS. Meta-analysis of safety for low event-rate binomial trials. Res Synth Methods. 2012;3(1):30\u201350.","journal-title":"Res Synth Methods"},{"issue":"29","key":"360_CR28","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","volume":"29","author":"T Stijnen","year":"2010","unstructured":"Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29(29):3046\u201367.","journal-title":"Stat Med"},{"key":"360_CR29","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley; 2019."},{"issue":"1","key":"360_CR30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, Russell LA. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53\u201377.","journal-title":"Stat Med"},{"issue":"22","key":"360_CR31","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","volume":"133","author":"L Cai","year":"2020","unstructured":"Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl). 2020;133(22):2665\u201373.","journal-title":"Chin Med J (Engl)"},{"issue":"10086","key":"360_CR32","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"4","key":"360_CR33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"360_CR34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","volume":"157","author":"BE Elewski","year":"2021","unstructured":"Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43\u201351.","journal-title":"JAMA Dermatol"},{"issue":"14","key":"360_CR35","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"9999","key":"360_CR36","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"2","key":"360_CR37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","volume":"5","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018;5(2):447\u201362.","journal-title":"Rheumatol Ther"},{"issue":"10142","key":"360_CR38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landewe","year":"2018","unstructured":"Landewe R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018;392(10142):134\u201344.","journal-title":"Lancet"},{"issue":"11","key":"360_CR39","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230\u20136.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"360_CR40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"10235","key":"360_CR41","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496\u2013505.","journal-title":"Lancet"},{"issue":"2","key":"360_CR42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2018.07.029","volume":"139","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and risk of inflammatory bowel disease in patients with psoriasis-a nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316\u201323.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"360_CR43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjd.14528","volume":"175","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Mallbris L, Warren RB, Bachelez H, Gislason GH, Hansen PR, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016;175(3):487\u201392.","journal-title":"Br J Dermatol"},{"key":"360_CR44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41927-018-0034-7","volume":"2","author":"A Kavanaugh","year":"2018","unstructured":"Kavanaugh A, Papp K, Gottlieb AB, de Jong E, Chakravarty SD, Kafka S, et al. Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry. BMC Rheumatol. 2018;2:29.","journal-title":"BMC Rheumatol"},{"issue":"2","key":"360_CR45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jphs.12212","volume":"9","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Song X, Kim G, Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J Pharm Health Serv Res. 2018;9(2):115\u201321.","journal-title":"J Pharm Health Serv Res"},{"key":"360_CR46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-clinpsy-050212-185522","volume":"9","author":"AM Hussong","year":"2013","unstructured":"Hussong AM, Curran PJ, Bauer DJ. Integrative data analysis in clinical psychology research. Annu Rev Clin Psychol. 2013;9:61\u201389.","journal-title":"Annu Rev Clin Psychol"},{"issue":"9","key":"360_CR47","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351\u201375.","journal-title":"Stat Med"},{"key":"360_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/art.41923","author":"L Penso","year":"2021","unstructured":"Penso L, Bergqvist C, Meyer A, Herlemont P, Weill A, Zureik M, et al. Risk of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis initiating interleukin 17 inhibitors: a nationwide population-based study using the French national health data system. Arthritis Rheumatol. 2021. https:\/\/doi.org\/10.1002\/art.41923.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"360_CR49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/eb-2018-102911","volume":"21","author":"O Efthimiou","year":"2018","unstructured":"Efthimiou O. Practical guide to the meta-analysis of rare events. Evid Based Ment Health. 2018;21(2):72\u20136.","journal-title":"Evid Based Ment Health"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00360-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-021-00360-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00360-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T22:11:26Z","timestamp":1636236686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-021-00360-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00360-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]},"assertion":[{"value":"17 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}